Cargando…

The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting

BACKGROUND/AIMS: The most common cancer among men and the third most common among women in Saudi Arabia is colon cancer. This study aimed to evaluate the yield of the fecal occult blood test (FOBT) used as a screening tool for colon cancer. SETTINGS AND DESIGN: Medical records of all patients above...

Descripción completa

Detalles Bibliográficos
Autores principales: Almoneef, Naif M., Alkhenizan, Abdullah H., Mahmoud, Ahmed S., Alsoghayer, Suad A., Aldheshe, Abdulaziz A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638621/
https://www.ncbi.nlm.nih.gov/pubmed/36352920
http://dx.doi.org/10.4103/jfmpc.jfmpc_16_22
_version_ 1784825460372275200
author Almoneef, Naif M.
Alkhenizan, Abdullah H.
Mahmoud, Ahmed S.
Alsoghayer, Suad A.
Aldheshe, Abdulaziz A.
author_facet Almoneef, Naif M.
Alkhenizan, Abdullah H.
Mahmoud, Ahmed S.
Alsoghayer, Suad A.
Aldheshe, Abdulaziz A.
author_sort Almoneef, Naif M.
collection PubMed
description BACKGROUND/AIMS: The most common cancer among men and the third most common among women in Saudi Arabia is colon cancer. This study aimed to evaluate the yield of the fecal occult blood test (FOBT) used as a screening tool for colon cancer. SETTINGS AND DESIGN: Medical records of all patients above the age of 50 years who had visited the Family Medicine clinic at King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia and who had undergone the FOBT screening between January 2002 and March 2017 were retrospectively reviewed. MATERIALS AND METHODS: We collected patients’ demographic data, FOBT results, and colonoscopy pathology reports results. STATISTICAL ANALYSIS: Data were analyzed using the Statistical Package for Social Science Version 25 (IBM Corp., Armonk, NY, USA). RESULTS: We included 2179 patients in this study. The mean age was 59.8 ± 8 years. As a result of the FOBT screening, 19.7% of the patients had a positive FOBT. Colon cancer accounted for 3.5% of all abnormal colonoscopy pathology reports. The Saudi age-standardized incidence rate (ASIR) in our study was 26.56 per 100,000 persons. CONCLUSION: FOBT is a feasible tool that can be used for colon cancer screening in primary care settings. The Saudi ASIR in our study was higher than the Saudi Cancer Registry, but it was still lower in comparison to other countries. We recommend the establishment of a national community-based colon cancer screening program.
format Online
Article
Text
id pubmed-9638621
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-96386212022-11-08 The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting Almoneef, Naif M. Alkhenizan, Abdullah H. Mahmoud, Ahmed S. Alsoghayer, Suad A. Aldheshe, Abdulaziz A. J Family Med Prim Care Original Article BACKGROUND/AIMS: The most common cancer among men and the third most common among women in Saudi Arabia is colon cancer. This study aimed to evaluate the yield of the fecal occult blood test (FOBT) used as a screening tool for colon cancer. SETTINGS AND DESIGN: Medical records of all patients above the age of 50 years who had visited the Family Medicine clinic at King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia and who had undergone the FOBT screening between January 2002 and March 2017 were retrospectively reviewed. MATERIALS AND METHODS: We collected patients’ demographic data, FOBT results, and colonoscopy pathology reports results. STATISTICAL ANALYSIS: Data were analyzed using the Statistical Package for Social Science Version 25 (IBM Corp., Armonk, NY, USA). RESULTS: We included 2179 patients in this study. The mean age was 59.8 ± 8 years. As a result of the FOBT screening, 19.7% of the patients had a positive FOBT. Colon cancer accounted for 3.5% of all abnormal colonoscopy pathology reports. The Saudi age-standardized incidence rate (ASIR) in our study was 26.56 per 100,000 persons. CONCLUSION: FOBT is a feasible tool that can be used for colon cancer screening in primary care settings. The Saudi ASIR in our study was higher than the Saudi Cancer Registry, but it was still lower in comparison to other countries. We recommend the establishment of a national community-based colon cancer screening program. Wolters Kluwer - Medknow 2022-08 2022-08-30 /pmc/articles/PMC9638621/ /pubmed/36352920 http://dx.doi.org/10.4103/jfmpc.jfmpc_16_22 Text en Copyright: © 2022 Journal of Family Medicine and Primary Care https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Almoneef, Naif M.
Alkhenizan, Abdullah H.
Mahmoud, Ahmed S.
Alsoghayer, Suad A.
Aldheshe, Abdulaziz A.
The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting
title The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting
title_full The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting
title_fullStr The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting
title_full_unstemmed The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting
title_short The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting
title_sort yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638621/
https://www.ncbi.nlm.nih.gov/pubmed/36352920
http://dx.doi.org/10.4103/jfmpc.jfmpc_16_22
work_keys_str_mv AT almoneefnaifm theyieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting
AT alkhenizanabdullahh theyieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting
AT mahmoudahmeds theyieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting
AT alsoghayersuada theyieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting
AT aldhesheabdulaziza theyieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting
AT almoneefnaifm yieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting
AT alkhenizanabdullahh yieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting
AT mahmoudahmeds yieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting
AT alsoghayersuada yieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting
AT aldhesheabdulaziza yieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting